Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
41 studies found for:    Open Studies | "intraocular melanoma"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "intraocular melanoma"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Iris Melanoma;   Stage I Intraocular Melanoma;   Stage IIA Intraocular Melanoma;   Stage IIB Intraocular Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIC Intraocular Melanoma
Interventions: Drug: Sunitinib;   Drug: Valproic Acid
2 Recruiting Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma;   Stage IV Intraocular Melanoma
Interventions: Drug: trametinib;   Drug: Akt inhibitor GSK2141795;   Other: pharmacological study;   Other: laboratory biomarker analysis
3 Recruiting New Biopsy Technique for Uveal Melanoma
Condition: Uveal Melanoma
Intervention:
4 Recruiting Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma
Condition: Uveal Melanoma
Intervention:
5 Recruiting Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
Condition: Uveal Melanoma
Intervention: Drug: AEB071
6 Recruiting Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients
Condition: Uveal Melanoma
Intervention: Biological: autologous dendritic cells electroporated with mRNA
7 Not yet recruiting Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma
Conditions: Macular Edema;   Cystoid Macular Edema;   Uveal Melanoma;   Radiation Maculopathy;   Radiation Retinopathy
Interventions: Drug: Ozurdex;   Drug: Bevacizumab
8 Recruiting Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
Conditions: Metastatic;   Uveal Melanoma
Interventions: Drug: 75mg selumetinib;   Drug: placebo;   Drug: Dacarbazine
9 Recruiting Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma
Condition: Uveal Melanoma, Monosomy 3 Positive, no Evidence for Metastases.
Intervention: Biological: Autologous Dendritic Cells loaded with autologous Tumor RNA
10 Unknown  Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye
Condition: Intraocular Melanoma
Interventions: Biological: bevacizumab;   Drug: temozolomide;   Genetic: polymorphism analysis;   Other: pharmacogenomic studies
11 Recruiting Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Condition: Uveal Melanoma
Intervention: Drug: crizotinib
12 Recruiting RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
Condition: Uveal Melanoma
Intervention: Drug: RAD001 (Everolimus) and Pasireotide (SOM230) LAR
13 Recruiting A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma
Condition: Uveal Melanoma
Interventions: Drug: Placebo;   Drug: Sorafenib
14 Recruiting A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
Condition: Uveal Melanoma
Interventions: Drug: AEB071;   Drug: MEK162
15 Recruiting Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy
Condition: Uveal Melanoma
Interventions: Dietary Supplement: CITICOLINE;   Dietary Supplement: PLACEBO
16 Recruiting Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma
Condition: Uveal Melanoma
Intervention: Radiation: Hypofractionated linear accelerator radiotherapy
17 Unknown  A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma
Condition: Metastatic Uveal Melanoma
Interventions: Drug: Dacarbazine;   Drug: Sunitinib
18 Recruiting Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery
Conditions: Extraocular Extension Melanoma;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma;   Recurrent Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIA Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIB Melanoma;   Stage IIIC Intraocular Melanoma;   Stage IIIC Melanoma;   Stage IV Intraocular Melanoma;   Stage IV Melanoma
Interventions: Drug: axitinib;   Other: laboratory biomarker analysis
19 Recruiting SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver
Condition: Stage IV Uveal Melanoma
Intervention: Device: Sir-Spheres®
20 Recruiting BAP1 Testing in Instance Choroidal Nevi or Uveal Melanoma
Condition: Choroidal Nevi, Uveal Melanoma
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years